SYM FINANCIAL Corp Purchases 50 Shares of West Pharmaceutical Services, Inc. $WST

SYM FINANCIAL Corp grew its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 5.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,027 shares of the medical instruments supplier’s stock after purchasing an additional 50 shares during the quarter. SYM FINANCIAL Corp’s holdings in West Pharmaceutical Services were worth $225,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in WST. Teacher Retirement System of Texas increased its stake in shares of West Pharmaceutical Services by 3.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 10,981 shares of the medical instruments supplier’s stock valued at $2,403,000 after acquiring an additional 392 shares in the last quarter. Y Intercept Hong Kong Ltd increased its stake in shares of West Pharmaceutical Services by 81.4% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 14,874 shares of the medical instruments supplier’s stock valued at $3,254,000 after acquiring an additional 6,676 shares in the last quarter. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group increased its stake in shares of West Pharmaceutical Services by 18.7% in the 2nd quarter. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group now owns 3,790 shares of the medical instruments supplier’s stock valued at $829,000 after acquiring an additional 598 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in shares of West Pharmaceutical Services by 7.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 34,828 shares of the medical instruments supplier’s stock valued at $7,620,000 after acquiring an additional 2,489 shares in the last quarter. Finally, Linden Thomas Advisory Services LLC increased its stake in shares of West Pharmaceutical Services by 2.8% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 5,072 shares of the medical instruments supplier’s stock valued at $1,110,000 after acquiring an additional 140 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Price Performance

WST opened at $283.54 on Wednesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.87 and a quick ratio of 2.18. The company has a market capitalization of $20.40 billion, a price-to-earnings ratio of 42.01, a P/E/G ratio of 4.12 and a beta of 1.07. The firm’s fifty day moving average price is $260.89 and its two-hundred day moving average price is $235.79. West Pharmaceutical Services, Inc. has a 1 year low of $187.43 and a 1 year high of $348.90.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.29. The firm had revenue of $804.60 million for the quarter, compared to the consensus estimate of $788.42 million. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. As a group, analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on WST. Evercore ISI lifted their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “outperform” rating in a research note on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft set a $345.00 price target on shares of West Pharmaceutical Services and gave the company a “buy” rating in a research note on Friday. Rothschild Redb upgraded shares of West Pharmaceutical Services to a “strong-buy” rating in a research note on Monday, September 15th. Weiss Ratings restated a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Tuesday, October 14th. Finally, KeyCorp boosted their price target on shares of West Pharmaceutical Services from $325.00 to $350.00 and gave the company an “overweight” rating in a research note on Friday, October 24th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $349.11.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.